tetano
Editor, Senior Moderator
BMC Pulm Med
. 2024 Jul 29;24(1):366.
doi: 10.1186/s12890-024-03183-7. SARS-CoV-2 viremia but not respiratory viral load is associated with respiratory complications in patients with severe COVID-19
Lingye Chen[SUP] 1 [/SUP], Lyra B Olson[SUP] 2 [/SUP], Ibtehaj A Naqvi[SUP] 3 [/SUP], Bruce A Sullenger[SUP] 3 [/SUP], Loretta G Que[SUP] 1 [/SUP], Thomas N Denny[SUP] 1 4 [/SUP], Bryan D Kraft[SUP] 5 [/SUP]
Affiliations
Background: Severe COVID-19 carries a high morbidity and mortality. Previous studies have shown an association between COVID-19 severity and SARS-CoV-2 viral load (VL). We sought to measure VL in multiple compartments (urine, plasma, lower respiratory tract) in patients admitted to the intensive care unit (ICU) with severe COVID-19 pneumonia and correlate with clinical outcomes.
Methods: Plasma, urine, and endotracheal aspirate (ETA) samples were obtained on days 1, 3, 7, 14, and 21 from subjects admitted to the ICU with severe COVID-19. VL was measured via reverse transcriptase polymerase chain reaction. Clinical data was collected from the electronic health record. Grouped comparisons were performed using Student's t-test or 1-way ANOVA. Linear regression was used to correlate VL from different compartments collected at the same time. Logistic regression was performed to model ventilator-freedom at 28 days as a function of peak plasma VL.
Results: We enrolled 57 subjects with severe COVID-19 and measured VL in plasma (n = 57), urine (n = 25), and ETA (n = 34). Ventilator-associated pneumonia developed in 63% of subjects. 49% of subjects were viremic on study day 1. VL in plasma and ETA both significantly decreased by day 14 (P < 0.05), and the two were weakly correlated on study day 1 (P = 0.0037, r[SUP]2[/SUP] = 0.2343) and on all study days (P < 0.001, r[SUP]2[/SUP] = 0.2211). VL were not detected in urine. While no associations were observed with peak ETA VL, subjects with higher peak plasma VL experienced a greater number of respiratory complications, including ventilator-associated pneumonia and fewer ventilator-free and hospital-free days. There was no association between VL in either plasma or ETA and mortality. In viremic patients, plasma VL was significantly lower in subjects that were ICU-free and ventilator-free (P < 0.05), with trends noted for hospital-freedom, ventilator-associated pneumonia, and survival to discharge (P < 0.1). By logistic regression, plasma VL was inversely associated with ventilator-freedom at 28 days (odds ratio 0.14, 95% confidence interval 0.02-0.50).
Conclusions: Elevated SARS-CoV-2 VL in the plasma but not in the lower respiratory tract is a novel biomarker in severe COVID-19 for respiratory complications.
Keywords: Biomarkers/blood; COVID-19; COVID-19 nucleic acid testing; Pneumonia; Respiration, artificial; Ventilator-associated pneumonia.
. 2024 Jul 29;24(1):366.
doi: 10.1186/s12890-024-03183-7. SARS-CoV-2 viremia but not respiratory viral load is associated with respiratory complications in patients with severe COVID-19
Lingye Chen[SUP] 1 [/SUP], Lyra B Olson[SUP] 2 [/SUP], Ibtehaj A Naqvi[SUP] 3 [/SUP], Bruce A Sullenger[SUP] 3 [/SUP], Loretta G Que[SUP] 1 [/SUP], Thomas N Denny[SUP] 1 4 [/SUP], Bryan D Kraft[SUP] 5 [/SUP]
Affiliations
- PMID: 39080682
- PMCID: PMC11288013
- DOI: 10.1186/s12890-024-03183-7
Background: Severe COVID-19 carries a high morbidity and mortality. Previous studies have shown an association between COVID-19 severity and SARS-CoV-2 viral load (VL). We sought to measure VL in multiple compartments (urine, plasma, lower respiratory tract) in patients admitted to the intensive care unit (ICU) with severe COVID-19 pneumonia and correlate with clinical outcomes.
Methods: Plasma, urine, and endotracheal aspirate (ETA) samples were obtained on days 1, 3, 7, 14, and 21 from subjects admitted to the ICU with severe COVID-19. VL was measured via reverse transcriptase polymerase chain reaction. Clinical data was collected from the electronic health record. Grouped comparisons were performed using Student's t-test or 1-way ANOVA. Linear regression was used to correlate VL from different compartments collected at the same time. Logistic regression was performed to model ventilator-freedom at 28 days as a function of peak plasma VL.
Results: We enrolled 57 subjects with severe COVID-19 and measured VL in plasma (n = 57), urine (n = 25), and ETA (n = 34). Ventilator-associated pneumonia developed in 63% of subjects. 49% of subjects were viremic on study day 1. VL in plasma and ETA both significantly decreased by day 14 (P < 0.05), and the two were weakly correlated on study day 1 (P = 0.0037, r[SUP]2[/SUP] = 0.2343) and on all study days (P < 0.001, r[SUP]2[/SUP] = 0.2211). VL were not detected in urine. While no associations were observed with peak ETA VL, subjects with higher peak plasma VL experienced a greater number of respiratory complications, including ventilator-associated pneumonia and fewer ventilator-free and hospital-free days. There was no association between VL in either plasma or ETA and mortality. In viremic patients, plasma VL was significantly lower in subjects that were ICU-free and ventilator-free (P < 0.05), with trends noted for hospital-freedom, ventilator-associated pneumonia, and survival to discharge (P < 0.1). By logistic regression, plasma VL was inversely associated with ventilator-freedom at 28 days (odds ratio 0.14, 95% confidence interval 0.02-0.50).
Conclusions: Elevated SARS-CoV-2 VL in the plasma but not in the lower respiratory tract is a novel biomarker in severe COVID-19 for respiratory complications.
Keywords: Biomarkers/blood; COVID-19; COVID-19 nucleic acid testing; Pneumonia; Respiration, artificial; Ventilator-associated pneumonia.